We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blocking Colorectal Cancer Growth by Inhibiting Glycosphingolipid Synthesis

By LabMedica International staff writers
Posted on 21 Jan 2019
Results of a recent study suggested that inhibition of glycosphingolipid (GSL) synthesis could be a novel approach for the treatment of colorectal cancer.

For several years, investigators at Johns Hopkins University (Baltimore, MD, USA) have been studying the role in human colorectal cancer of the oncogenic signal transducer enzyme, beta-1,4-galactosyltransferase-V (beta-1,4-GalT-V). More...
This enzyme catalyzes the synthesis of lactosylceramide, a fat that can produce superoxides, which lead to an increase in new cells and blood vessels that cancers can exploit to spread.

The investigators reported in a paper published in the January 8, 2019, issue of the journal Biochemical and Biophysical Research Communications that beta-1,4-GalT-V gene/protein expression was specifically increased in human colorectal cancer tumors, compared to visibly normal tissue. In addition there was a marked increase in its enzymatic activity, and its product lactosylceramide. Furthermore, there were increased dihydrosphingolipid metabolites, in particular dihydrosphingomyelin in cancer tissue compared to normal.

These findings were obtained by analyzing 24 colorectal cancer tissue samples. The investigators evaluated the samples' response to antibodies against beta-1,4GalT-V and found strong reactivity. An ELISA (enzyme-linked immunosorbent assay) test to detect and measure antibodies in 21 of these samples indicated an approximately 6.5-fold increase of beta-1,4GalT-V in colorectal cancer tissues compared with visibly normal areas within the same samples. There was a 2.25-fold increase in lactosylceramide synthase activity in colorectal cancer samples compared with normal colon cells.

Inhibition of glycosphingolipid synthesis by the synthetic ceramide analog, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP), concurrently inhibited colorectal cancer cell (HCT-116) proliferation, as well as beta-1,4-GalT-V mass and several glycosphingolipid levels. These findings strengthen the hypothesis that inhibition of GSL synthesis could be a novel approach for the treatment of this life-threatening disease.

"We know that beta-1,4GalT-V is highly and specifically enriched on the endothelial cells in the lining of blood vessels, in cancer tissue," said first author Dr. Subroto B. Chatterjee, professor of pediatrics at Johns Hopkins University. "If you treat these cells with a drug that targets beta-1,4GalT-V, it will go and attack the endothelial cells that have this protein, and hopefully it will neutralize their activity. This provides evidence that beta-1,4GalT-V is a target for cell proliferation, and that we can block the cycle of cell proliferation by using this D-PDMP compound, at least in cell-based testing. It shows the potential for the application of this compound in perhaps multiple types of cancers."

Related Links:
Johns Hopkins University


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Urine Drug Test
Instant-view® Phencyclidine Urine Drug Test
New
Glucose Tolerance Test
NERL Trutol
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New automated lab procedures can detect opioids in tiny amounts of blood (Photo courtesy of Tripathi Lab/Brown University)

First-Of-Its-Kind Quantitative Method Assesses Opioid Exposure in Newborns

As the opioid crisis continues to impact communities across the United States, laboratories encounter significant difficulties in accurately detecting opioid substances in individuals with opioid use disorder.... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: T cell immunity could be a marker for early Parkinson’s treatment (Photo courtesy of Shutterstock)

T Cells in Blood Can Detect Parkinson's Years Before Diagnosis

Diagnosing Parkinson’s disease before the appearance of motor symptoms remains one of neurology’s most significant challenges. Patients can go years—even decades—without a diagnosis, as subtle early indicators... Read more

Microbiology

view channel
Image: A prototype of the lateral flow test (Photo courtesy of University of Exeter)

POC Lateral Flow Test Detects Deadly Fungal Infection Faster Than Existing Techniques

Diagnosing mucormycosis—an aggressive and often deadly fungal infection—remains a major challenge due to the disease’s rapid progression and the lack of fast, accurate diagnostic tools. The problem became... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.